Literature DB >> 11810508

Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline.

Y. Niki1, K. Hashiguchi, Naoyuki Miyashita, Masamitsu Nakajima, Toshiharu Matsushima.   

Abstract

The influence of gatifloxacin, a new quinolone antibacterial, on the pharmacokinetics of theophylline (TP) was studied in five healthy adult male volunteers. After 200 mg of TP in sustained-release preparation was administered twice daily for 4 consecutive days, the same dose of TP and 200 mg of gatifloxacin were administered concurrently to the subjects twice daily for 5 consecutive days. Comparison of the pharmacokinetic parameters on day 4 of TP alone, and days 3 and 5 of co-administration revealed no significant differences in the maximum concentrations (Cmax), areas under the serum concentration-time curve (AUC0-12), total body clearances, and the amounts and proportions of TP and its metabolites in urine. One subject, however, showed 55% and 44% increases in Cmax and AUC0-12, respectively, on day 5 of co-administration relative to values on day 4 of TP alone. Thus, co-administration of gatifloxacin seemed to have little effect on the pharmacokinetics of TP. Further studies will be necessary to clarify the pharmacokinetic interaction between quinolones and TP, and it is recommended that, when both gatifloxacin and TP are administered, the background of the patients, such as their age, liver and cardiac functions, and other concomitant medications, be considered.

Entities:  

Year:  1999        PMID: 11810508     DOI: 10.1007/s101560050026

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  4 in total

Review 1.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  The influence of a newly developed quinolone: antofloxacin, on CYP activity in rats.

Authors:  Xiao Xu; Hai-Yan Liu; Li Liu; Lin Xie; Xiao-Dong Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jan-Mar       Impact factor: 2.441

3.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

4.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.